Duopharma Biotech: A Beacon of Innovation in Malaysia’s Healthcare Landscape, Celebrated by Frost & Sullivan
Highlights: Duopharma Biotech Berhad, a leading pharmaceutical company in Malaysia, was awarded the 2022 Malaysian Company of the Year by Frost & Sullivan for its contributions to the halal pharmaceutical industry. The company, established in 1978, specializes in manufacturing, R&D, and marketing of over 300 generic drugs and consumer healthcare products. It has diversified into biosimilars, with ERYSAA® being a notable product for treating anemia in chronic kidney disease. The halal pharmaceutical market, valued at $100 billion in 2021, is projected to reach $129 billion by 2025. In 2021, ERYSAA® sales grew by 52% and it was prescribed in about 49% of dialysis centers and hospitals. Duopharma Biotech is also involved in halal pharmaceutical awareness campaigns and international collaborations. It scored 98% on the customer satisfaction index and is part of the Sectoral Working Group introduced by the Halal Development Corporation Berhad (HDC) in 2021. The company aims to become a global thought leader in halal pharmaceuticals.
Link to Original Article: